[The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].

A daily dose of alfusosine (an uroselective blocker alpha-l-adrenoreceptors produced as dalfas by Synthelabo Group, France) was given for 12 weeks to 124 patients with benign prostatic hyperplasia. The patients were examined before the treatment and on the treatment week 4, 8 and 12. The response (improved quality of life, higher rate of urine flow, smaller amount of residual urine in the bladder) was achieved in 120 (96%) patients. Alfusosine effect was more pronounced in patients with severe defects of urination. The drug was well tolerated, side effects observed in 7(5.6%) patients were mild and did not require treatment discontinuation. Alfusosine is indicated in benign prostatic hyperplasia with moderate infravesical obstruction, significantly disturbed urination caused by hypertonicity of bladder cervix smooth muscles, posterior urethra and prostate.